One page, thousands of outlets. See who else covered it.
EyePoint’s experimental eye treatment came up short of Eylea, the current go-to option for wet age-related macular degeneration, according to results of a Phase 3 trial. The company’s shares {$EYPT} dropped 70% when markets opened ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.
Health Canada has authorized a drug to treat moderate to severe hot flashes and night sweats in breast cancer patients. Elinzanetant, also known by the brand name Lynkuet, was first approved in July…
Though its drug missed the main goal of a wet AMD study, EyePoint, as well as analysts, still see a path toward approval. Investors may be harder to win over, however.
Air crew have more radiation-related cancer deaths than any other profession, write Vishal R. Patel, Christopher Worsham, and Anupam B. Jena.
A new study tracked more than 500 teens showing that relationships between them and their pet dogs helped with stress and anxiety.
Opioids can be highly effective at relieving moderate to severe pain, whether it comes from surgery, an injury or conditions such as cancer.
A new study from London Health Sciences Centre Research Institute (LHSCRI) shows that expanded genetic testing can help match cancer patients with more personalized treatment options, with nearly one…